Natick-based Boston Scientific announced that the first patient has been enrolled to study the company’s newest product to treat coronary artery disease.
The study includes the company’s TAXUS Liberte drug-coated stent system along with a combination of therapy drugs. The stent system allows for more consistent drug distribution, according to the company.
Co-sponsors of the study include Indiana pharmaceutical company Eli Lilly and Co. and Daiichi Sankyo Inc. of New Jersey, the manufacturers of Effient, one of the drugs used with the stent system. The first patient to be a part of the study is in Lansing, Mich.
Results of the study will also be contributed to a joint study between the U.S. Food and Drug Administration, drug and device manufacturers and Harvard Clinical Research Institute.
